STOCK TITAN

Cadrenal Therapeutics Inc - CVKD STOCK NEWS

Welcome to our dedicated news page for Cadrenal Therapeutics (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cadrenal Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cadrenal Therapeutics's position in the market.

Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has appointed Jeff Cole as the Chief Operating Officer to oversee manufacturing, supply chain operations, intellectual property, commercialization strategies, and partnering activities for tecarfarin, a novel Vitamin K Antagonist for anticoagulation therapy. With over 25 years of experience in global pharmaceutical manufacturing and commercial operations, Mr. Cole's appointment is expected to support the company's tecarfarin clinical program and evaluate partnering opportunities. His previous roles at Valeant Pharmaceuticals International and Espero BioPharma demonstrate a strong track record in product development, supply, and commercial operations. The appointment reflects the company's focus on addressing unmet needs for patients with left ventricular assist devices (LVADs), antiphospholipid syndrome (APS), end-stage kidney disease (ESKD), and atrial fibrillation (AFib).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.47%
Tags
management clinical trial
-
Rhea-AI Summary
Cadrenal Therapeutics, Inc. announces the citation of a peer-reviewed article in the Journal of the American College of Cardiology highlighting the need for VKA-based anticoagulant therapy. The article emphasizes the limitations of DOACs in conditions such as mechanical heart valves, thrombotic APS, and AFib associated with ESKD. It also underscores the need for the advancement of tecarfarin development program to address critical gaps in anticoagulation therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (CVKD) announced that its Chief Medical Officer will participate in a fireside chat at the Lytham Partners 2024 Investor Select Conference. The company will also host one-on-one meetings with investors. The webcasted fireside chat is scheduled for February 1, 2024, and can be accessed online. Management will be participating in virtual one-on-one meetings throughout the event. Further information on the conference is available at the provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.22%
Tags
conferences
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) will present tecarfarin, a late-stage oral anticoagulant, at Biotech Showcase™ 2024 and the J.P. Morgan 42nd Annual Healthcare Conference. Tecarfarin targets orphan diseases, providing stable anticoagulation for patients with conditions like End-Stage Kidney Disease, Left Ventricular Assist Devices, and Antiphospholipid Syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
-
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has received an 'Outperform' rating and a price target of US$4.00 per share from Noble Capital Markets for its late-stage novel oral anticoagulant tecarfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain orphan diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none
-
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has engaged The Sage Group to explore strategic partnerships, co-development, and licensing agreements for tecarfarin, a novel oral and reversible anticoagulant. Tecarfarin addresses the need for stable anticoagulation in patients with certain orphan diseases, including ESKD with AFib, LVADs, and APS. The drug has shown promising results in clinical trials and has been granted orphan drug and fast-track designations by the FDA. Cadrenal estimates the combined addressable market opportunity to be in excess of US $2 billion per year in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced their CEO, Quang Pham, will present at NobleCon19, discussing their late-stage novel oral anticoagulant tecarfarin designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare medical conditions. The presentation will be available via high-definition video webcast on the company's website and other platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
conferences
-
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) provided a corporate update on tecarfarin, a novel oral anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots. Tecarfarin's expanded focus includes rare medical conditions such as ESKD with AFib, LVADs, and APS, representing a market opportunity of over $2 billion annually in the U.S. The company also highlighted the need for a new VKA at the recent European Society of Cardiology Congress and completed a $7.5 million private placement. Q3 2023 operating expenses totaled $989,000, with $628,000 cash used in operating activities. Cash balances were $9.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
earnings
-
Rhea-AI Summary
The 26th BioFlorida Annual Conference highlighted the growth and success of Florida's life sciences industry. The conference featured discussions on various topics including medical innovations, advancements in neurodegeneration, and financing insights. BioFlorida also announced a strategic partnership with BIOQuébec. The conference recognized individuals and organizations for their achievements and presented awards in different categories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
Rhea-AI Summary
The 26th BioFlorida Annual Conference highlighted the growth and success of Florida's life sciences industry. The conference featured discussions on various topics including medical innovations, advancements in neurodegeneration, and financing insights. BioFlorida also announced a strategic partnership with BIOQuébec. The conference recognized individuals and organizations for their achievements and presented awards in different categories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
Cadrenal Therapeutics Inc

Nasdaq:CVKD

CVKD Rankings

CVKD Stock Data

9.52M
4.98M
57.82%
4.43%
1.51%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Ponte Vedra